Taking the hallucinogen psilocybin may boost positive feelings like bliss or a sense of oneness with the universe, but the authors question whether these feelings amount to genuine mystical experience or spiritual growth. The work examines the distinction between drug-induced altered states and authentic spiritual or mystical development, suggesting that the subjective experiences produced by psilocybin might not reflect true spiritual progress.
A psychiatrist warns that the evidence for psychedelic medicine rests on small, selective pilot studies and is weak, while sensationalized accounts downplay serious risks such as triggering a psychotic episode or misuse in vulnerable populations. The author argues that these drugs can distort perceptions and alter conscious interpretations in unpredictable ways, and that expediting FDA approval of psychedelics is alarming given the ongoing catastrophe from mass-marketed opioids and the public health impact of other reality-altering substances. The piece calls for balanced scientific analysis and support for basic neuroscience rather than rushing to embrace each new trend.
Large-scale trials with careful oversight and risk-modification strategies are needed to counter risks in psychedelic medicine. Many compounds like ketamine, MDMA, and psilocybin have been tested only in small patient series, are difficult to blind, and have been studied by highly committed investigators rather than in larger populations. These agents have a complex history of nonmedical or illegal use, leading to Schedule 1 restrictions. Careful studies, appropriate regulatory processes, and skilled clinical judgment can help protect against enthusiasms that have not always proved valuable. There may be much to learn about mental functioning while affected by these compounds.